General Project Description. The Parties contemplate that the Research Program will include the following steps and activities: (a) DPC will furnish to 3DP the structure and activity data on chemical compounds screened against a Target, including both compounds that are active ("Hits") and compounds that are inactive against the Target. (b) 3DP will use its DirectedDiversity? Technology to compute a chemical descriptor matrix to describe and map the compounds for which DPC provides data. 3DP also will develop a Structure Activity Relationship ("SAR") model based on this descriptor matrix for Hits. (c) 3DP will compare the SAR model with compounds in 3DP Accessible Libraries, and 3DP will identify [**] compounds to be synthesized by 3DP and supplied to DPC for testing. 3DP will supply between [**] milligrams of each such compound in 96 deep well plates (about 80 compounds per plate). These compounds will meet a minimum purity of [**] of the compounds provided. Upon request of DPC, 3DP will provide additional quality control for individual compounds. (d) 3DP will provide DPC with a secure internet based communication channel to provide activity or other compound related data to 3DP. (e) 3DP will develop an improved SAR model based on the testing data provided by DPC. This improved SAR will be used to perform iterative rounds of selection and synthesis of compounds from 3DP Accessible Libraries, and/or to develop Custom Accessible Libraries from which compounds will be selected and synthesized, and/or to perform preliminary medicinal chemistry optimization and synthesis. Such compounds will be supplied to DPC for additional testing in furtherance of the Research Program.
Appears in 2 contracts
Sources: Collaborative Discovery and Lead Optimization Agreement (3 Dimensional Pharmaceuticals Inc), Collaborative Discovery and Lead Optimization Agreement (3 Dimensional Pharmaceuticals Inc)
General Project Description. The Parties contemplate that the Research Program will include the following steps and activities:
(a) DPC will furnish to 3DP the structure and activity data on chemical compounds screened against a Target, including both compounds that are active ("Hits") and compounds that are inactive against the Target.
(b) 3DP will use its DirectedDiversity? Technology to compute a chemical descriptor matrix to describe and map the compounds for which DPC provides data. 3DP also will develop a Structure Activity Relationship ("" SAR") model based on this descriptor matrix for Hits.
(c) 3DP will compare the SAR model with compounds in 3DP Accessible Libraries, and 3DP will identify [**] compounds to be synthesized by 3DP and supplied to DPC for testing. 3DP will supply between [**] milligrams of each such compound in 96 deep well plates (about 80 compounds per plate). These compounds will meet a minimum purity of [**] of the compounds provided. Upon request of DPC, 3DP will provide additional quality control for individual compounds.]
(d) 3DP will provide DPC with a secure internet based communication channel to provide activity or other compound related data to 3DP.
(e) 3DP will develop an improved SAR model based on the testing data provided by DPC. This improved SAR will be used to perform iterative rounds of selection and synthesis of compounds from 3DP Accessible Libraries, and/or to develop Custom Accessible Libraries from which compounds will be selected and synthesized, and/or to perform preliminary medicinal chemistry optimization and synthesis. Such compounds will be supplied to DPC for additional testing in furtherance of the Research Program.
Appears in 1 contract
Sources: Collaborative Discovery and Lead Optimization Agreement (3 Dimensional Pharmaceuticals Inc)